













460HMGB1 and TLR4 mediate skeletal muscle
recovery in a murine model of hindlimb ischemia
Ulka Sachdev, MD,b Xiangdong Cui, MS,b and Edith Tzeng, MD,a,b Pittsburgh, Pa
Background:Wehave previously shown that the danger signal high-mobility group box 1 (HMGB1) promotes angiogenesis
when administered to ischemic muscle. HMGB1 signals through Toll-like receptor 4 (TLR4) as well as the receptor for
advanced glycation end-products (RAGE). However, the actions of these receptors in ischemic injury and muscle recovery
are not known. We hypothesize that TLR4 mediates tissue recovery and angiogenesis in response to ischemia.
Methods: Femoral artery ligation was performed in control, TLR4 competent (C3H/HeOuJ) and incompetent (C3H/
HeJ) mice, as well as RAGE knockout mice and their C57B6 control counterparts. In other experiments, control mice
were pretreated with anti-HMGB1 neutralizing antibody before femoral artery ligation. After 2 weeks, limb perfusion
was evaluated using laser Doppler perfusion imaging and reported as the ratio of blood ﬂow in the ischemic to non-
ischemic limb. Muscle necrosis, fat replacement, and vascular density in the anterior tibialis muscle were quantiﬁed
histologically. In vitro, TLR4 and RAGE expression was evaluated in human dermal microvascular endothelial cells in
response to hypoxia. Human dermal microvascular endothelial cells treated with HMGB1 alone and in the presence of
anti-TLR4 antibody were probed for phosphorylated extracellular signal-regulated kinase (ERK), a signaling molecule
critical to endothelial cell (EC) angiogenic behavior.
Results: Both anti-HMGB1 antibody as well as defective TLR4 signaling in HeJ mice resulted in prominent muscle
necrosis 2 weeks after femoral artery ligation. Control HeOuJ mice had less necrosis than TLR4 incompetent HeJ mice,
but a greater amount of fat replacement. In contrast to control C3H mice, control C57B6 mice demonstrated prominent
muscle regeneration with very little necrosis. Muscle regeneration was not dependent on RAGE. While vascular density
did not differ between strains, mice with intact RAGE and TLR4 signaling had less blood ﬂow in ischemic limbs
compared with mutant strains. In vitro, EC TLR4 expression increased in response to hypoxia while TLR4 antagonism
decreased HMGB1-induced activation of extracellular signal-regulated kinase.
Conclusions: Both HMGB1 and TLR4 protect against muscle necrosis after hindlimb ischemia. However, muscle
regeneration does not appear to be tied to vascular density. HMGB1 likely activates angiogenic behavior in ECs in vitro,
and this activation may be modulated by TLR4. The improvement in blood ﬂow seen in mice with absent TLR4 and
RAGE signaling may suggest anti-angiogenic roles for both receptors, or vasoconstriction induced by TLR4 and RAGE
mediated inﬂammatory pathways. (J Vasc Surg 2013;58:460-9.)
Clinical Relevance: Nonreconstructable peripheral artery disease causes signiﬁcant functional disability and is associated
with a high risk of limb loss. The mechanisms that govern muscle recovery and angiogenesis after ischemia are important
to understand to improve medical therapy for patients who cannot have an intervention. This article evaluates the role of
high-mobility group box 1 and the innate immune receptor Toll-like receptor 4 inmediatingmuscle recovery after ischemia.
While high-mobility group box 1 has been shown to mediate end-organ damage in other clinical scenarios, it may also play
an important role in regenerative processes such as myocyte regeneration and angiogenesis.Peripheral artery disease causes signiﬁcant functional
disability and can result in limb loss within 6 months of diag-
nosis in 25% to 40% of patients who present with nonrecon-
structable disease.1 Responses to limb ischemia include
arteriogenesis, angiogenesis, and muscle regeneration.2
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Fig 1. C57BL6 (A) and C3H/HeOuJ (B)mice underwent femoral artery ligation on the right hindlimb and exposure
of the femoral vessels without ligation on the left. Anterior tibialis muscles were harvested from both sides after sacriﬁce
at 24 hours after femoral ligation. Parafﬁn sections were stained for high-mobility group box 1 (HMGB1) (arrow).
C, Quantiﬁcation of HMGB1 staining nuclei (arrow) was expressed as % total nuclei (*P < .001; yP < .05; n ¼ 4-5;
scale bar¼ 50 mm). Western blots for HMGB1 were performed on nuclear (D) and cytoplasmic (E) fractions of skeletal
muscle from C3H/HeOuJ mice. Animal number refers to individual mice within the experiment.
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limb ischemia and improve limb-salvage rates.
High-mobility group box-1 (HMGB1) is a ubiquitous
nuclear protein that can be released by both necrotic andstressed cells in response to hypoxia and other insults.5,6
Once released, it signals through select Toll-like receptors
(TLRs), including TLR2 and TLR4, as well as the receptor
for advanced glycation end-products (RAGE). HMGB1
Fig 2. A, C3H/HeOuJ mice were treated with intraperitoneal injection of polyclonal anti-high-mobility group box 1
(HMGB1) antibody (600 mg; n ¼ 9) or IgG (n ¼ 6) 30 minutes before femoral artery ligation. The anterior muscle
compartments of both limbs were harvested at day 14 for histologic analysis (asterisk ¼ necrotic muscle; scale bar ¼ 50
mm.B, Scatter plot of the % muscle necrosis identiﬁed in each mouse (error bars¼ standard error of the mean; *P¼ .02).
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injury and in hemorrhagic shock.7 Recent studies suggest
a role for HMGB1 and its receptors in angiogenesis and
potentially muscle regeneration.8-13 In our laboratory, we
have demonstrated that HMGB1 is released by endothelial
cells in response to hypoxia and promotes angiogenesis
when administered to ischemic mouse hindlimbs.8 Based
on this, we hypothesize that TLR4 mediates tissue recovery
and angiogenesis in response to ischemia. Thus, we evalu-
ated the roles of HMGB1, TLR4, and RAGE in promoting
neovascularization and muscle regeneration after limb
ischemia using a murine hindlimb ischemia model in this
current study. Murine hindlimb ischemia is generally well
tolerated due to compensatory arteriogenesis and angio-
genesis and is thus a relevant model for these studies.14
METHODS
Endothelial cells. Human dermal microvascular endo-
thelial cells (HDMVECs; VEC Technologies, Rensselaer,
NY) were cultured in OptiMem with heparin and endothe-
lial cell growth supplement. Cells were used between
passages 3 and 12. Preliminary experiments have demon-
strated that early and late passages within this time framebehave similarly. Serum depletion was performed in Dul-
becco’s modiﬁed Eagle’s medium with 1% fetal bovine
serum for 3 to 6 hours.
Reagents. Recombinant HMGB1 (rHMGB1) was
derived from yeast using a modiﬁcation of the vector YEp-
FLAG as described15 and used at a dose of 1 mg/mL,
which promotes endothelial tube formation.8 HMGB1 was
stored in formulation buffer (25 mM Tris chloride pH 8,
150 mM KCl, 2 mM dithiothreitol, 10% glycerol), which
was used a control for rHMGB1 administration. Polyclonal
HMGB1 blocking antibody, a generous gift from Dr Kevin
Tracey (Feinstein Institute for Medical Research, Man-
hasset, NY), was developed in rabbit and afﬁnity-puriﬁed as
previously described.16 Control rabbit polyclonal IgG was
obtained from Sigma (St. Louis, Mo). Growth-factor
reduced Matrigel (BD Biosciences, San Jose, Calif) was
stored at 4C, and allowed to solidify on either 24 well
plates or glass coverslips for 30 minutes in a 37C standard
incubator. Neutralizing antibodies against TLR2 and
TLR4 were obtained from Biolegend (San Diego, Calif).
Antibodies for immunohistochemistry were obtained from
the following companies: Abcam, Cambridge, Mass (anti-
HMGB1, anti-RAGE); eBiosciences, San Diego, Calif
Fig 3. A, Calf muscles from ischemic hindlimbs of HeJ and HeOuJ mice obtained at day 14 were parafﬁn embedded
and stained for von Willebrand factor (vWF) (red). Note areas of fat replacement (arrow), and muscle necrosis
(asterisk). Scale bar ¼ 50 mm. B, Quantiﬁcation of vascular density (vessels per high power ﬁeld [HPF]), % area muscle
regeneration, necrosis, and fat replacement in HeOuJ and HeJ mice. Values are obtained from four to ﬁve images per
section, three sections per animal; n ¼ 3-4 animals/group. (*P ¼ .03; yP ¼ .04).
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factor); and Vector Laboratories, Burlingame, Calif (Goat-
anti-rabbit secondary antibody). Alexa 488 was obtained
from Molecular Probes (Eugene, Ore), rhodamine-labeled
phalloidin from Invitrogen (Carlsbad, Calif), DRAQ 5
from Biostatus Limited (Bath, UK), and DAPI from Sigma
(St Louis, Mo).
Animals. Male C3H/HeJ (TLR4 incompetent; Stock
# 000659; n ¼ 9), C3H/HeOuJ (TLR4 competent; Stock
# 000635) and C57BL/6J mice (Stock # 000664) were
purchased from Jackson Laboratories (Bar Harbor, Me).
The C3H/HeJ mice express a mutant TLR4 receptor
and are not responsive to the TLR4 ligands lipopolysacchr-
ide or HMGB1. The C3H/HeOuJ mice are the wild-type
controls for this strain. RAGE KO (C57Bl/6J back-
ground) mice were generous gifts from Tim Oury, PhD
(University of Pittsburgh, Pittsburgh, Pa). All animalhousing and procedures were approved by the Institutional
Animal Use and Care Committee of the University of
Pittsburgh (protocol #0911093B-7). Mice were used at 12
weeks of age and weighed 20 to 40 g.
In vitro immunohistochemistry and confocal mic-
roscopy. HDMVECs were seeded onto gelatin-coated
glass coverslips and incubated in either normoxia or 1%
hypoxia for 6 or 24 hours. The hypoxic conditions were
achieved in a hypoxia chamber (COY Laboratory Prod-
ucts, Inc, Grass Lake, Mich). Desired hypoxia was regu-
lated by replacing ambient air in the chamber with
a mixture of humidiﬁed nitrogen (95%) and CO2 (5%)
until the set oxygen content was reached. The cells were
undisturbed for the duration of the hypoxia treatment to
maintain a consistent level of hypoxia during the experi-
ments. Cells were ﬁxed with 2% paraformaldehyde, per-
meabilized with 0.1% Triton X for 10 minutes and blocked
Fig 4. A, Calf muscle from control C57B6 and receptor for advanced glycation end-products (RAGE) knockout (KO)
mice were harvested 14 days after femoral ligation and stained for von Willebrand factor (vWF) (red) to evaluate
vascular density (scale bar ¼ 50 mm; n ¼ 4 each). B, Quantiﬁcation of number of vWF positive structures per high
power ﬁeld (HPF). Values are obtained from four to ﬁve images per section, three sections per animal.
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incubated with primary antibody to TLR4 or RAGE, as
well as rhodamine phalloidin and DRAQ-5 (Cell Signaling
Technology, Beverly, Mass) to evaluate the cytoskeleton
(phalloidin) and cell nuclei (DRAQ-5), respectively. Alexa
488-conjugated secondary antibody was used to detect
antigen staining. After mounting onto glass slides, four to
ﬁve images per coverslip were obtained at 400 using an
Olympus Provis II microscope (Olympus, Central Valley,
Pa) with Magnaﬁre image acquisition software (Olympus).
Western blot analysis. HDMVECs were treated with
HMGB1 or formulation buffer and lysed in phenylmetha-
nesulfonylﬂuoride at 30 minutes. Protein content was
quantiﬁed using BCA. Cell proteins were separated on
SDS-PAGE, transferred to nitrocellulose membranes and
immunoblotted for phosphorylated extracellular signal-
regulated kinase (ERK) and total ERK as a loading control.
Quantiﬁcation of relative band density was obtained using
Image J (National Institutes of Health, Washington, DC)
analysis programming.
Skeletal muscle obtained from ischemic and nonische-
mic hindlimbs after femoral artery ligation (see below)
were snap frozen in liquid nitrogen and stored at 80C
until use. For immunoblotting, muscles were homogenized
and lysed in phenylmethanesulfonylﬂuoride. Nuclear and
cytoplasmic fractions were separated as described 5 on14% SDS-PAGE. After transfer to nitrocellulose, Western
blot was performed on nuclear and cytoplasmic fractions
for HMGB1 and a-actin.
Murine hind-limb ischemia model. Femoral artery
ligation promotes robust angiogenic and arteriogenic
responses in mice14 and was used to evaluate ischemic
muscle injury and neovascularization in numerous studies.
We have chosen a 2-week time point for the maximum
duration of the ischemia because other studies have
demonstrated that mice achieve near maximal recovery of
perfusion at this time. Plateau occurs at about 21 days.14
Also, we have observed that muscle recovery is complete
by 2 weeks. Mice were anesthetized with pentobarbital
(0.1 cc/g intraperitoneal). Bilateral groins were shaved
and prepped with iodine prep solution. Transverse inci-
sions were made in each groin, and the femoral structures
were identiﬁed. On the right, the external iliac and
femoral veins and arteries, as well as all visible branches
were ligated with 6-0 silk,17 avoiding the femoral nerve.
On the left, the femoral vessels were exposed but not
ligated. Mice were sacriﬁced by overdose of inhaled iso-
ﬂurane and cervical dislocation either 24 hours or 14 days
later. In separate experiments, HeOuJ mice were injected
with 600 mg of either functional anti-HMGB-1 antibody
or control IgG before the initiation of hind-limb
ischemia. This dose has previously been shown to
Fig 5. Laser Doppler perfusion imaging was performed 14 days
after femoral artery ligation in (A) control and receptor for
advanced glycation end-products (RAGE) knockout (KO) mice
(n ¼ 4 each), as well as (B) HeOuJ and HeJ mice (n ¼ 6 each).
Perfusion recovery is shown as ratio between ischemic and non-
ischemic limb. *P < .05.
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reperfusion injury.5
Laser Doppler perfusion imaging. Mice were anes-
thetized with inhaled isoﬂurane, which was maintained
throughout the procedure. Heart rate and respiratory rate
were visually monitored to assess depth of anesthesia, and
animals were kept warm with a heating lamp. Excess hairs
were removed from the limb. The blood ﬂow to both hind-
limbs was measured using a Laser Doppler blood-ﬂow
meter (PERIMED III, Stockholm, Sweden). Three
sequential images were obtained, and the one demon-
strating the greatest perfusion to both extremities was
chosen for analysis. The entire hind limb starting from the
incision site proximally to the paw distally was incorporated
into the region of interest. Perfusion was expressed as
a ratio of the ischemic to nonischemic leg.
Histologic analysis. Tibialis anterior muscle was
removed at the time of sacriﬁce, ﬁxed in formalin,
parafﬁn-embedded and sectioned (8 mm thickness).
Sections were stained with hematoxylin and eosin for
morphologic evaluation. Three hematoxylin and eosin
sections 60 mm apart were digitally captured at 20 andevaluated for muscle necrosis, muscle regeneration, and fat
replacement using Metamorph image analysis program
(Molecular Devices, Downington, Pa); all quantiﬁcations
were performed in a blinded fashion. Muscle necrosis was
identiﬁed by loss of muscle architecture as well as inﬂam-
matory inﬁltrate. Regenerating muscle was characterized
by rounded shape and centrally located nuclei.18 Corre-
sponding sections were also stained with primary antibody
to HMGB1 in samples obtained at 4 hours and von Wil-
lebrand factor to quantify vascular density in samples ob-
tained after 14 days. After washing, sections were
incubated with biotinylated goat-anti-rat secondary anti-
body. ABC horseradish peroxidase reagent (Vector Labo-
ratories, Burlingame, Calif) was added after washing.
Antigen detection was performed by adding AEC chro-
mogen substrate, and sections were counterstained with
hematoxylin. Sections were photographed at 200
magniﬁcation. Vascular density was determined using
Metamorph and expressed as a value per high power ﬁeld
(HPF).
Statistical analysis. SigmaStat (San Jose, Calif) anal-
ysis program was used to evaluate statistical signiﬁcance
(P < .05). Analysis was performed using analysis of variance
or t-test.
RESULTS
Ischemia results in a sustained reduction in nuclear
HMGB1 in skeletal muscle. In our previous study,8
HMGB1 had prominent effects on endothelial cells when
given exogenously, and nuclear HMGB1 was reduced in
HeOuJ mice after as little as 4 hours of muscle ischemia. In
this experiment, muscle from both ischemic and non-
ischemic hindlimbs was examined for HMGB1 release 24
hours after arterial ligation to evaluate whether release
persists for longer than 4 hours. Similar to our previous
ﬁndings at 4 hours, ischemic muscle from both the TLR4
mutant and the control mice had signiﬁcantly reduced
nuclear HMGB1 content compared with the nonischemic
limb (Fig 1, A-C). Western blot conﬁrmed the reduction in
nuclear HMGB1 in ischemic muscle compared with non-
ischemic muscle (Fig 1, D). Beta-actin, which is involved in
chromatin remodeling complexes within the nucleus,19 was
used as a loading control and remained unchanged
regardless of ischemia. However, cytoplasmic fractions
from ischemic muscle did not demonstrate an increase in
HMGB1, suggesting that it was released extracellularly in
the setting of ischemia (Fig 1, E).
HMGB1 and TLR4 protect against muscle necro-
sis. We hypothesized that HMGB1 is mobilized and extra-
cellularly released to mediate muscle regeneration and
angiogenesis. We have previously reported that administra-
tion of exogenous HMGB1 into ischemic skeletal muscle
improved perfusion recovery and led to greater vascular
density. Additionally, we have demonstrated loss of nuclear
HMGB1 from both ischemic endothelial cells (ECs) and
ischemic myocytes.8 In the following experiments, we
evaluated the role of endogenous HMGB1 and its receptor
TLR4 on tissue responses 2 weeks after femoral artery
Fig 6. A, Human dermal microvascular endothelial cells (HDMVECs) were exposed to 1% hypoxia for 6 or 24 hours,
and probed for expression of either Toll-like receptor 4 (TLR4) or (B) receptor for advanced glycation end-products
(RAGE). Protein expression was determined using mean ﬂuorescence intensity normalized to actin. Percent change in
protein expression with hypoxia compared with air is depicted (C) (*P < .03; n ¼ 4/group).
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blocking antibody (n ¼ 9) developed signiﬁcantly more
muscle necrosis than mice treated with nonspeciﬁc IgG (n¼
6) (25.5%65.6 vs 5.2%63.6, respectively,P¼ .02; Fig 2,A
and B). Vessel density, as determined by von Willebrand
factor staining, did not differ between the treatment groups
(anti-HMGB1 [n¼ 6] 5.66 1.5/HPF; IgG [n¼ 4] 5.46
1.1). Similarly, TLR4-incompetent mice (HeJ) also devel-
oped greater areas of muscle necrosis in response to limb
ischemia. In contrast, the control mice (HeOuJ) developed
larger areas of fat replacement (Fig 3). Vascular density was
similar between HeJ and HeOuJ mice.
Loss of RAGE and TLR4 signaling in limb
ischemia improved limb perfusion but not muscle
recovery. The role of RAGE, another HMGB1 receptor,
was also examined. In contrast to the C3H strain ofmice, prominent muscle regeneration was observed in the
RAGE KO mice as well as their C57B6 controls. Architec-
turally, there was no difference between wild-type mice and
those lacking RAGE with neither group of mice developing
necrosis. Both had comparable amounts of fat replacement,
muscle regeneration, and vascular density 14 days after
femoral artery ligation (Fig 4). Thus, absence of RAGE or
TLR4 signaling did not improve muscle regeneration or
protect against necrosis. Paradoxically, mice lacking either
RAGE or TLR4 signaling had better return of blood ﬂow
in the ischemic hindlimbs than control mice as measured by
laser Doppler perfusion imaging (LDPI) (Fig 5).
Hypoxia results in increased expression of TLR4
but not RAGE in ECs. We have previously shown that
hypoxic endothelial cells mobilize HMGB1 from their
nuclei, similar to ﬁndings in hypoxic myocytes, and
Fig 7. A, Phosphorylated extracellular signal-regulated kinase
(P-ERK) and total ERK expression in human dermal microvascular
endothelial cells (HDMVECs) exposed to high-mobility group box
1 (HMGB1) over 1 hour. B-C, Percent change in P-ERK/total
ERK ratio with exposure to IgG, anti-Toll-like receptor (TLR)2,
and anti-TLR4 after 30 minutes; *P < .03; n ¼ 3.
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tubing.8 In this experiment, we evaluated the expression of
relevant HMGB1 receptors in ECs in response to normoxic
and hypoxic conditions. TLR4 and RAGE expression in
HDMVECs exposed to normal oxygen concentration or 1%
hypoxia was examined by immunohistochemistry. While
RAGE expression remained fairly stable under all the
conditions, TLR4 expression increased signiﬁcantly fol-
lowing 6 hours of hypoxia (Fig 6). Additionally, important
differences existed in the distribution of TLR4 and RAGE
within the cells. TLR4 appeared to be located in a perinuclear
fashion during normoxia but became more diffuse in
hypoxia. In contrast, RAGE staining was throughout the
cytoplasm under both conditions.
HMGB1 stimulates ERK activation inHDMVECs.
ERK is an important signal transduction pathway in EC
angiogenic behavior.20 Treatment of HDMVECs with
rHMGB1 resulted in sustained ERK phosphorylation forover 1 hour (Fig 7, A). In the presence of HMGB1 and the
TLR4 neutralizing antibody, ERK phosphorylation was
diminished. In contrast, treatment with control IgG or anti-
TLR2 antibody did not signiﬁcantly affect ERK activation
in HDMVECs (Fig 7, B and C). This effect was seen 30
minutes after incubation with HMGB1 and the antibodies.
CONCLUSIONS
HMGB1, a danger-associated molecular pattern that
has been shown to be released from cells during stress
and necrosis, has important cytokine-like functions
including the activation of the innate immune system
through TLRs and RAGE.7 The goal of this study was to
identify the role of HMGB1 and its receptors TLR4 and
RAGE in mediating recovery after muscle ischemia. Inter-
actions between HMGB1 and RAGE are critical to cell
migration in the central nervous system.21-24 In smooth
muscle cells, HMGB1 promotes cell migration through
actin cytoskeletal rearrangement.25 Systemically, extracel-
lular HMGB1 induced the migration and proliferation of
mesangioblasts.26 HMGB1 release may be through cell
injury/death, and it may also be actively secreted by
inﬂammatory cells. The secreted HMGB1 has been shown
to function in a cytokine type fashion, initiating a variety of
downstream inﬂammatory pathways. The release of
HMGB1 during cell damage may mediate regenerative
processes such as angiogenesis and muscle recovery after
an ischemic insult, which may have important implications
for patients with severe peripheral arterial disease who
cannot undergo revascularization. These effects may be
mediated by direct effects on skeletal muscle, endothelial
cells, progenitor cells, and/or immune cells. The role of
TLRs and RAGE on resident and bone-marrow derived
cells in ischemic muscle is an area of ongoing investigation
in our laboratory.
In vivo, our results suggest that for up to 24 hours after
the induction of ischemia, the loss of nuclear HMGB1
from muscle cells is prominent. HMGB1 does not appear
to be present in the sarcoplasm during this time, suggesting
that it is being released into the extracellular milieu. We
have not been able to detect HMGB1 in the serum by
Western blot in the setting of acute limb ischemia (data
not shown). This may be due to relatively low levels of
HMGB1 arising from the damaged skeletal muscle that is
sufﬁcient for local signaling in the local muscle bed. The
mechanisms governing HMGB1 release from skeletal
muscle are not clear but are likely due to direct cellular
injury or necrosis.7
Hypoxia inducible factor-1 alpha (HIF-1a), a cellular
sensor of low oxygen concentration which is stabilized by
hypoxia and promotes the transcription of angiogenic
proteins, promotes upregulation of RAGE in tumor cells.27
The role of HIF-1a in HMGB1 release was not investigated
in our current study, and there is no evidence in the litera-
ture to link these two molecules. Instead, there is evidence
that HIF-1a does have some interplay with TLR4 signaling
with reports indicating that lipopolysacchride signaling
through TLR4 requires HIF-1a to manifest signs of
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TLR4 activation in mediating dendritic cell maturation.29
These studies favor a role for HIF-1a in downstream
TLR4 signaling which needs to be examined in the setting
of hindlimb ischemia.
Interestingly, neutralization of HMGB1 as well as
impaired TLR4 signaling both resulted in marked muscle
necrosis that was still prominent 2 weeks after femoral artery
ligation. These data suggest that HMGB1 released in the
setting of ischemia is critical in promoting muscle recovery,
potentially through TLR4 mediated pathways, at either
a local or systemic level. The severity of muscle necrosis
appeared to be independent of vascular density, which did
not differ between control or TLR4 mutant mice. The
release of local HMGB1 following ischemia may recruit
regenerativemesenchymal stem cells or circulating endothe-
lial progenitor cells that can contribute to muscle regenera-
tion and angiogenesis. This hypothesis is supported by the
ﬁnding that HMGB1 enhanced homing of mesangioblasts
to dystrophic muscle.30 HMGB1 has also been shown to
promote homing of endothelial progenitor cells to ischemic
muscle and tumors.31
Both HMGB1 and TLR4 have been shown to
promote cardiac remodeling after ischemia and have been
associated with decreased ﬁbrosis and improved angiogen-
esis at the ischemic border. However, in cardiac ischemia-
reperfusion, HMGB1 and TLR4 both mediate worse
outcomes, presumably by driving an exaggerated inﬂam-
matory response. It has been postulated that in ischemia
without reperfusion, HMGB1 and TLR4 drive recovery,
which may be important therapeutically.32 Interestingly,
TLR4 polymorphisms have been associated with differing
levels of cardiac functional recovery in patients with dilated
cardiomyopathy, which may have implications for patients
with critical limb ischemia.33 This has not been extensively
investigated in the literature to date.
Although HMGB1-RAGE interactions are known to
be important in the recovery of the nervous system
following injury, RAGE does not appear to play a signiﬁcant
role in muscle regeneration after ischemia. RAGE KO mice
exhibited muscle histology that was indistinguishable from
control animals following hind limb ischemia. However, it
is difﬁcult to compare the ﬁndings between the RAGE KO
and the TLR4 mutant mice because the parental strain
responses differ greatly in their responses to ischemia.
The parent strain for the RAGE KO mice tolerated muscle
ischemia well with robust muscle regeneration and little
necrosis. Strain differences in muscle regeneration after
ischemia are well described in mice and may be related to
regenerative capacity as well as to an arteriogenic potential
that can restore earlier tissue perfusion and limit ischemic
injury.34
Although absent RAGE and impaired TLR4 signaling
offered no advantage over controls in terms ofmuscle regen-
eration, both groups demonstrated improvements in perfu-
sion recovery compared with their controls, without
differences in vessel density. These ﬁndings would suggest
that angiogenesis following ischemia is not regulated byRAGE or TLR4 signaling. Instead, TLR4 and RAGE
signaling may negatively regulate arteriogenesis, which has
a greater ability to restore distal perfusion than angiogen-
esis.35 The regulation of arteriogenesis by TLR4 and/or
RAGE will be the focus of future investigations. Alternative
explanations for the paradoxical LDPI ﬁndings exist.
Because LDPI is a measurement of cutaneous perfusion, it
is also possible that activation of inﬂammatory pathways
through RAGE and TLR4may result in cutaneous vasocon-
striction, which abates in the absence of these inﬂammatory
signaling pathways. Thus, the relationship between cuta-
neous perfusion and vascular density in muscle may not be
linear, particularly when evaluating inﬂammatorymediators.
The ability of hypoxia to upregulate TLR4 expression
on ECs in vitro supports the potential for TLR4 to play
an important role in mediating vascular responses.
Although RAGE expression was not altered in hypoxia, it
is abundantly expressed in ECs and may still be an impor-
tant receptor. In conjunction with our ﬁnding that ECs
also release HMGB1 in the setting of ischemia, these
data suggest a potential autocrine or paracrine mechanism
in which HMGB1 released by ECs can mediate vascular
responses to ischemia or ﬂow changes derived from
vascular occlusion, possibly through TLR4, in ECs or
vascular smooth muscle cells. In support of this hypothesis,
exogenous HMGB1 promotes ERK activation, which is
critical for endothelial tube formation. In the setting of
TLR4 antagonism, HMGB1 results in an initial peak of
ERK phosphorylation followed by a signiﬁcant nadir.
Thus, effects of HMGB1 on EC that are mediated by
TLR4 are likely to be temporal and context speciﬁc.
In summary, TLR4 and HMGB1 appear to play a role
in muscle protection and regeneration after muscle
ischemia. Our in vivo data also suggest that muscle regen-
eration is not dependent on angiogenesis. A plausible
hypothesis is that HMGB1 mobilizes stem cells in
a TLR4-dependent manner. The ability of HMGB1 to
recruit mesenchymal stem cells has been previously
described.30 Alternatively, HMGB1-TLR4 interactions
may be important in arteriogenesis or collateral formation,
which was also not speciﬁcally addressed in this study. Of
interest, lack of TLR4 or RAGE resulted in improved
perfusion recovery after ischemia. Thus, RAGE and
TLR4 may mediate cutaneous vasoconstriction after injury,
which may, in part, be a consequence of actions on endo-
thelial and perivascular cells. Further studies are required to
determine how interaction of HMGB1with both RAGE
and TLR4 may play a role in mediating muscle recovery
and angiogenesis after ischemic injury.AUTHOR CONTRIBUTIONS
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